Similar findings were reported by another group using the human BL cell line Ramos, which showed that the signals that provide the competitive advantage to BCR-positive BL cells involve interactions between LYN, SYK, CD19, and CD79B [110]. The gene discussed is CD19; the disease is Burkitt lymphoma.